Credit Suisse Ag Verastem, Inc. Transaction History

Credit Suisse Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.57 - $4.85 $47,234 - $89,138	-18,379 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$1.9 - $2.82 $60,287 - $89,478	-31,730 Reduced 63.32%	18,379 $45,000
Q4 2020 Feb 12, 2021	BUY	$1.15 - $2.4 $24,029 - $50,148	20,895 Added 71.52%	50,109 $106,000
Q3 2020 Nov 13, 2020	SELL	$1.11 - $1.68 $10,301 - $15,592	-9,281 Reduced 24.11%	29,214 $35,000
Q2 2020 Aug 12, 2020	BUY	$1.69 - $4.2 $65,056 - $161,679	38,495 New	38,495 $66,000
Q3 2019 Nov 12, 2019	SELL	$1.21 - $1.59 $19,886 - $26,131	-16,435 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$1.25 - $3.14 $1,613 - $4,053	-1,291 Reduced 7.28%	16,435 $24,000
Q1 2019 May 14, 2019	BUY	$2.79 - $4.09 $13,601 - $19,938	4,875 Added 37.93%	17,726 $52,000
Q4 2018 Feb 13, 2019	BUY	$3.23 - $7.01 $41,508 - $90,085	12,851 New	12,851 $43,000
Q3 2018 Nov 13, 2018	SELL	$6.86 - $9.97 $129,153 - $187,705	-18,827 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.88 - $8.67 $54,221 - $163,230	18,827 New	18,827 $130,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.29B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.